Apr 1 |
Korro to Participate in Upcoming Investor Conferences
|
Mar 26 |
Korro Bio GAAP EPS of -$53.08
|
Mar 26 |
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
|
Feb 27 |
BMO starts Korro at outperform, cites upcoming data for AATD drug
|
Feb 27 |
Korro to Present at the TD Cowen 44th Annual Health Care Conference
|
Feb 18 |
Korro Bio: An Interesting Platform With A Very Long Horizon
|
Feb 6 |
Private equity firms are Korro Bio, Inc.'s (NASDAQ:KRRO) biggest owners and were rewarded after market cap rose by US$161m last week
|
Jan 18 |
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio
|